Download A4Medicine Mobile App
Empower Your RCGP AKT Journey: Master the MCQs with Us! 🚀
This table summarises the risks and benefits of injectable contraceptives with their respective evidence gradings as listed by FSRH. It is important to understand that this is a summary and there may be individual patient factors that could influence the choice and use of these contraceptives.
| Aspect | Description and Evidence | Grading of Recommendations |
|---|---|---|
| Benefits | ||
| Efficacy | The failure rate is around 0.2% with correct use and about 6% with typical use. | Evidence-based on randomised controlled trials |
| Menstrual Benefits | Amenorrhoea or reduced bleeding is common, benefiting those with menstrual problems. DMPA may also reduce pain linked to endometriosis. | Evidence-based on other robust experimental or observational studies |
| Cancer Protection | DMPA isn't linked with a heightened risk of ovarian or endometrial cancer and may offer protection. | Good Practice Point |
| Sickle Cell Disease | It's a contraceptive option for women with sickle cell disease and may diminish the severity of sickle crisis pain. | Evidence is limited but relies on expert opinion |
| Risks | ||
| Bone Mineral Density (BMD) | Use is connected with a small loss in BMD, which is typically regained after stopping. | Evidence-based on randomised controlled trials |
| Breast Cancer Risk | There's a potential link between hormonal contraception (including progestogen-only injectables) and a slight increase in breast cancer... |
Try our Free Plan to get the full article.
